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iscussion
r Joshua Robert Sonett (New York, NY). Dr Petersen, I con-
ratulate you and your colleagues on a nicely presented, well
ritten, and, I believe, important article. The Duke oncology
atabase has enabled the largest review of a single-center result of
ulmonary metastasectomy in melanoma. Importantly, the data-
ase includes both nonsurgical and surgical patients in the cohort.
he primary variable analysis was performed on 318 patients
ndergoing resection, a carefully selected cohort representing 18%
f all patients with pulmonary metastasis in your center. The
esults of the analysis are reassuring, nicely corroborating the
revious work presented by Ugo Pastorini of the international
egistry of lung metastases, a collaboration of US, Canadian, and
uropean centers. That collaborative registry was created to facil-
tate the study of results of pulmonary metastasectomy and to
ivine prognostic variables to guide treatment, much as your study
as. When the data were presented in 1997 with 5000 cases, 282
epresented patients with melanoma who underwent curative re-
ection. Overall survival of resected patients in that study was 21%
t 5 years. And although patients with melanoma histologic type
ad the worst prognosis of all those with solid tumors in that
eview, the nearly identical 5-year survival results presented today
learly confirm and validate the utility of pulmonary metastasec-
omy for select patients with metastatic melanoma. Additionally,
he international registry reported a follow-up study of 328 patients
n which four groups of risk-stratified variables were defined to
elp set the standards for delineating the role of metastasectomy in
elanoma. Again, these results and stratifications are nicely sim-
lar to your reported results, with the additional risk factors that
ou added of nodular histologic type and extrathoracic metastasis.
hat brings me to my first question.
Classically and sensibly, pulmonary metastasectomy with cur-
tive intent is reserved for patients without any evidence of ex- o
The Journal of Thoracicrathoracic disease. In your series, 20% of your patients undergo-
ng resection were defined as having other distant metastases.
lease explain why you brought these patients to resection and
ow you would deal with them in the future.
Two, given the similar results of the prognostic groups in the
nternational registry data, how do you think the addition of
odular histologic type helps us to decide which patients with
etastatic melanoma should undergo pulmonary resection or the
linical timing of the potential resection?
And finally, you noted that in the age of improved imaging your
roup preferentially now uses video-assisted thoracoscopic surgi-
al techniques for pulmonary metastasectomy. I wholeheartedly
upport this approach, but historically video-assisted thoracoscopic
urgical pulmonary metastasectomy has been considered contro-
ersial. Can you comment on this?
Again, I congratulate you on a well done and well presented
tudy, and thank the Association for the privilege of discussing this
resentation.
Dr Petersen. Thank you, Dr Sonett, for your insightful com-
ents and questions.
With regard to your first question about our 19% rate of
xtrathoracic metastasis, all such patients who underwent surgery
ither had a history of previous extrapulmonary resection or un-
erwent concurrent extrapulmonary resection. Although the rate
eems high at 19%, it is similar to the rate reported by Leo and
olleagues in the subset analysis of patients with melanoma only of
he international registry of lung metastases. The larger study by
astorino and colleagues, which included a variety of tumor types,
ctually showed a trend toward worse prognosis for patients with
revious or concurrent extrapulmonary resections, which is con-
istent with the findings in our study.
With regard to your question of how to use some of these
redictors that we have discriminated in our multivariate model,
uch as nodular histologic type or disease-free interval, one of the
gures that we presented revealed varying survival curves when
tratifying by number of preoperative risk factors. We believe it is
mportant to take into consideration all risk factors when deciding
hether the patient should undergo surgery. For instance if a
atient had nodular histologic type of the primary tumor but had a
rolonged disease-free interval, a limited number of pulmonary
etastases, and no evidence of extrathoracic disease, we would not
e dissuaded from surgery but would inform the patient of the
lightly higher mortality relative to patients without that risk
actor.
With regard to your last question about thoracoscopic surgery,
t is true that this subject remains controversial. We realize this is
ot standard of practice at many other institutions. Of the 318
atients with metastasis who underwent surgical resection in our
eries, 40 underwent resection by a thoracoscopic approach. All
hese patients were evaluated preoperatively by combined PET-CT
can, resulting in a low likelihood of having missed lesions larger
han 3 mm. The sensitivity of finding pulmonary metastasis from
elanoma by combined PET-CT scan has been previously re-
orted by Finkelstein and colleagues to be around 88%, with a
pecificity of 91%. The worst-case scenario for the small number
f patients with missed lesions not found by preoperative imaging
ould be to undergo a sequential thoracoscopic resection. More-
ver, there is no evidence to date that these missed lesions, found
and Cardiovascular Surgery ● Volume 133, Number 1 109
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G
TSntraoperatively by manual palpation through an open approach
nd probably measuring on the order of 3 mm or less, given the
ewest generation of high-resolution CT imaging and combination
ET-CT scan, are of any detriment to the patient.
Dr Mark J. Krasna (Baltimore, Md). Excellent presentation
nd good answers to those questions. Just one quick comment. In
oth colon cancer and renal cell carcinoma, we now have data on
he importance of lymph node metastasis. At many centers, we
ave actually begun to implement routine mediastinoscopy before
ttempting a curative metastasectomy. Although it only panned out
n your univariate analysis and did not show up in the Cox
egression analysis, would you comment on how you evaluate the
ediastinum in these patients with metastatic melanoma before
hey are taken to metastasectomy?
Dr Petersen. The regional lymph node status that showed up as
significant predictor in our univariate analysis had to do with the
rimary tumor only. The significance of positive mediastinal
ymph nodes to which you are alluding to remains unclear, how-
ver, especially in the setting of metastatic disease. Unfortunately,
his will never be answered unless lymph node dissection in
atients with pulmonary metastatic melanoma is uniformly prac-
iced. A maximum of only 9% of patients in the international
egistry of lung metastases underwent mediastinal lymph node
issection. Because currently most patients with suspected pulmo-
ary metastatic melanoma undergo wide margin wedge resection
nly without previous mediastinoscopy or concurrent lymph node
issection, this question will remain largely unanswered until we
ave a known denominator. e
10 The Journal of Thoracic and Cardiovascular Surgery ● JanuDr Frank C. Detterbeck (New Haven, Conn). I just want to
ollow up on Dr Sonett’s comment about video-assisted resection. We
nd others have shown that you still need to do palpation, even with
elical CT, because approximately 20% to 25% of patients will have
dditional metastases found on palpation despite helical CT. We have
one a follow-up study trying to look at factors that might have
redicted that. Was it that the radiologists were undercalling it? We
ave not been able to identify factors. So I think that if you are trying
o do a complete resection, you still need to palpate.
You must have decided that you weren’t going to try to do a
omplete resection; you were just going to see how many patients
ad follow-up nodules. Have you gone back and actually looked at
hat to provide some data on that?
Dr Petersen. No, we have not specifically looked at that
uestion in the metastasectomy series, but that is a very good point
nd something that we can look into in the future. The patients in
ur study that underwent thoracoscopic resection were evaluated
reoperatively with the latest generation of high-resolution CT and
ombined PET-CT. It is becoming standard practice at our insti-
ution to evaluate these patients with combined PET-CT, which as
e have previously discussed has high sensitivity and specificity,
aking it less likely to miss lesions larger than 3 mm. Unfortu-
ately, to date there are no data to support that going after all of the
ery small lesions that may or may not be found by aggressive
ntraoperative manual palpation through an open approach im-
roves overall prognosis. In fact, the likelihood of false positives
ncreases the smaller the lesion is, and by aggressively resecting all
hese, you may actually be jeopardizing pulmonary reserve; how-
ver, this remains largely unknown.
ary 2007
